SCHEMBL2184971

SCHEMBL2184971

CC(C)(C)c1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N(C3(OC=O)CCCC3)C4)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 4/20 0.40
LMNA P02545 2/20 0.40
HDAC3 O15379 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TP53 P04637 2/20 0.39
TRPV1 Q8NER1 6/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
LPL P06858 1/20 0.38
LIPC P11150 1/20 0.38
LIPE Q05469 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179546 0.89 NPC1 (0.42) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL2179901 0.89 SLC2A1 (0.42) RAB9ANPC1
SCHEMBL2197181 0.89 HDAC4 (0.33) HDAC6
SCHEMBL2178868 0.88 SLC2A1 (0.42) RAB9ANPC1
SCHEMBL13719341 0.88 MEN1 (0.44) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL13718920 0.87 TRPV1 (0.48) MAPTTRPV1
SCHEMBL2178670 0.85 SLC2A1 (0.43) MEN1KMT2ARAB9ANPC1
SCHEMBL2177810 0.85 KDM4E (0.41) MAPTSMN1; SMN2TP53TRPV1RAB9A
SCHEMBL13719331 0.85 MAPT (0.41) MEN1KMT2AMAPTLMNAHDAC3
SCHEMBL2184969 0.85 MEN1 (0.45) MEN1KMT2AMAPTLMNAHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT MEN1 3071/4885KMT2A 1705/4885MAPT 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.